scholarly journals Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada

2006 ◽  
Vol 176 (1) ◽  
pp. 47-53 ◽  
Author(s):  
D. M. Skowronski ◽  
Y. Li ◽  
S. A. Tweed ◽  
T. W.S. Tam ◽  
M. Petric ◽  
...  
Keyword(s):  
British Columbia ◽  
Avian Influenza ◽  
Antibody Response ◽  
Human Antibody ◽  
Protective Measures

scholarly journals COVID-19 Vaccine mRNABNT162b2 Elicits Human Antibody Response in Milk of Breastfeeding Women

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 785
Author(s):  
Maurizio Guida ◽  
Daniela Terracciano ◽  
Michele Cennamo ◽  
Federica Aiello ◽  
Evelina La Civita ◽  
...  
Keyword(s):  
Breast Milk ◽  
Antibody Response ◽  
Human Milk ◽  
Human Antibody ◽  
Serum Antibodies ◽  
Serum Samples ◽  
Low Concentration ◽  
Milk Samples ◽  
Milk Antibodies ◽  
Roche Diagnostics

Objective: The objective of this research is to demonstrate the release of SARS-CoV-2 Spike (S) antibodies in human milk samples obtained by patients who have been vaccinated with mRNABNT162b2 vaccine. Methods: Milk and serum samples were collected in 10 volunteers 20 days after the first dose and 7 seven days after the second dose of the mRNABNT162b2 vaccine. Anti-SARS-CoV-2 S antibodies were measured by the Elecsys® Anti-SARS-CoV-2 S ECLIA assay (Roche Diagnostics AG, Rotkreuz, Switzerland), a quantitative electrochemiluminescence immunometric method. Results: At first sample, anti-SARS-CoV-2 S antibodies were detected in all serum samples (103.9 ± 54.9 U/mL) and only in two (40%) milk samples with a low concentration (1.2 ± 0.3 U/mL). At the second sample, collected 7 days after the second dose, anti-SARS-CoV-2 S antibodies were detected in all serum samples (3875.7 ± 3504.6 UI/mL) and in all milk samples (41.5 ± 47.5 UI/mL). No correlation was found between the level of serum and milk antibodies; the milk antibodies/serum antibodies ratio was on average 2% (range: 0.2–8.4%). Conclusion: We demonstrated a release of anti-SARS-CoV-2 S antibodies in the breast milk of women vaccinated with mRNABNT162b2. Vaccinating breastfeeding women could be a strategy to protect their infants from COVID-19 infection.

scholarly journals Heavily Isotype-Dependent Protective Activities of Human Antibodies against Vaccinia Virus Extracellular Virion Antigen B5

2009 ◽  
Vol 83 (23) ◽  
pp. 12355-12367 ◽  
Author(s):  
Mohammed Rafii-El-Idrissi Benhnia ◽  
Megan M. McCausland ◽  
John Laudenslager ◽  
Steven W. Granger ◽  
Sandra Rickert ◽  
...  
Keyword(s):  
Antibody Response ◽  
Vaccinia Virus ◽  
Smallpox Vaccine ◽  
Human Antibody ◽  
Human Mabs ◽  
Complement Components ◽  
Vaccinia Virion ◽  
Virion Antigen

ABSTRACT Antibodies against the extracellular virion (EV or EEV) form of vaccinia virus are an important component of protective immunity in animal models and likely contribute to the protection of immunized humans against poxviruses. Using fully human monoclonal antibodies (MAbs), we now have shown that the protective attributes of the human anti-B5 antibody response to the smallpox vaccine (vaccinia virus) are heavily dependent on effector functions. By switching Fc domains of a single MAb, we have definitively shown that neutralization in vitro—and protection in vivo in a mouse model—by the human anti-B5 immunoglobulin G MAbs is isotype dependent, thereby demonstrating that efficient protection by these antibodies is not simply dependent on binding an appropriate vaccinia virion antigen with high affinity but in fact requires antibody effector function. The complement components C3 and C1q, but not C5, were required for neutralization. We also have demonstrated that human MAbs against B5 can potently direct complement-dependent cytotoxicity of vaccinia virus-infected cells. Each of these results was then extended to the polyclonal human antibody response to the smallpox vaccine. A model is proposed to explain the mechanism of EV neutralization. Altogether these findings enhance our understanding of the central protective activities of smallpox vaccine-elicited antibodies in immunized humans.

scholarly journals A refined genome phage display methodology delineates the human antibody response in Chagas disease patients

iScience ◽  
2021 ◽  
pp. 102540
Author(s):  
André Azevedo Reis Teixeira ◽  
Luis Rodriguez Carnero ◽  
Andréia Kuramoto ◽  
Fenny Hui Fen Tang ◽  
Carlos Hernique Gomes ◽  
...  
Keyword(s):  
Antibody Response ◽  
Phage Display ◽  
Chagas Disease ◽  
Human Antibody

scholarly journals Human Immunoglobulin G Cannot Inhibit Fibrinogen Binding by the Genetically Diverse A Domain ofStaphylococcus aureusFibronectin-Binding Protein A

mSphere ◽  
2018 ◽  
Vol 3 (2) ◽  
pp. e00590-17
Author(s):  
P. Martijn den Reijer ◽  
Mehri Tavakol ◽  
Nicole Lemmens-den Toom ◽  
Dikra Allouch ◽  
Sheila Thomas ◽  
...  
Keyword(s):  
Antibody Response ◽  
Virulence Factor ◽  
Antibody Production ◽  
Immunoglobulin G ◽  
Binding Protein ◽  
Protein A ◽  
Sequence Diversity ◽  
Enzyme Linked Immunosorbent Assay ◽  
Human Antibody ◽  
Fibrinogen Binding

ABSTRACTThe fibronectin-binding protein A (FnBPA) is a cell surface-associated protein ofStaphylococcus aureuswhich mediates adherence to the host extracellular matrix and is important for bacterial virulence. Previously, substantial sequence diversity was found among strains in the fibrinogen-binding A domain of this protein, and 7 different isotypes were described. The effect of this sequence diversity on the human antibody response, in terms of both antibody production and antibody function, remains unclear. In this study, we identify five different FnBPA A domain isotypes based on the sequence results of 22 clinicalS. aureusisolates, obtained from the same number of patients suffering from bacteremia. Using a bead-based Luminex technique, we measure the patients’ total immunoglobulin G (IgG) against the 7 FnBPA isotypes at the onset and during the time course of bacteremia (median of 10 serum samples per patient over a median of 35 days). A significant increase in IgG against the FnBPA A domain, including the isotype carried by the infecting strain, is observed in only three out of 22 patients (14%) after the onset of bacteremia. Using a Luminex-based FnBPA–fibrinogen-binding assay, we find that preincubation of recombinant FnBPA isotypes with IgG from diverse patients does not interfere with binding to fibrinogen. This observation is confirmed using an alternative Luminex-based assay and enzyme-linked immunosorbent assay (ELISA).IMPORTANCEDespite the manyin vitroand murinein vivostudies involving FnBPA, the actual presence of this virulence factor during human infection is less well established. Furthermore, it is currently unknown to what extent sequence variation in such a virulence factor affects the human antibody response and the ability of antibodies to interfere with FnBPA function. This study sheds new light on these issues. First, the uniform presence of a patient’s IgG against FnBPA indicates the presence and importance of this virulence factor duringS. aureuspathogenesis. Second, the absence of an increase in antibody production in most patients following bacteremia indicates the complexity ofS. aureus-host interactions, possibly involving immune evasion or lack of expression of FnBPA during invasive infection. Finally, we provide new insights into the inability of human antibodies to interfere with FnBPA-fibrinogen binding. These observations should be taken into account during the development of novel vaccination approaches.

scholarly journals Human Illness and Isolation of Low‐Pathogenicity Avian Influenza Virus of the H7N3 Subtype in British Columbia, Canada

2006 ◽  
Vol 193 (6) ◽  
pp. 899-900 ◽  
Author(s):  
Danuta M. Skowronski ◽  
S. Aleina Tweed ◽  
Martin Petric ◽  
Tim Booth ◽  
Yan Li ◽  
...  
Keyword(s):  
British Columbia ◽  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Human Illness

Human Antibody Response Following Multiple Injections of Bovine Collagen

1991 ◽  
Vol 87 (6) ◽  
pp. 1080-1088 ◽  
Author(s):  
David H. Frank ◽  
Leslie Vakassian ◽  
Jack C. Fisher ◽  
Nuri Ozkan
Keyword(s):  
Antibody Response ◽  
Human Antibody ◽  
Multiple Injections ◽  
Bovine Collagen

VACCINATION AS PRIMARY CONTACT WITH INFLUENZA A AND B VIRUSES

PEDIATRICS ◽  
1949 ◽  
Vol 3 (2) ◽  
pp. 208-213
Author(s):  
RAE V. NICHOLAS ◽  
WERNER HENLE
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Influenza A ◽  
Infectious Agents ◽  
Older Individuals ◽  
Protective Measures ◽  
Primary Contact ◽  
Small Doses ◽  
Antibody Levels ◽  
Booster Effect

A single dose of 0.5 ml. of commercially available influenzal virus vaccine injected into children from seven weeks to three years of age produced antibodies in about 70%. Resulting antibody levels in the children, most of whom were born after the last widespread epidemics of influenza A and B, were distinctly lower than those observed in older individuals who, in all likelihood, had experienced previous contacts with influenzal antigens. Two injections at a week's interval failed to result in a better antibody response in these children in agreement with the experience gained in adults. Increase in the dose of vaccine appears unwarranted now, since the incidence of febrile reactions—all of short duration—exceeded 40%. This inferior antibody response may be the result of several factors: (a) the smaller dose of vaccine which can be safely administered to such children; (b) the possible inferior immune response of the younger individual; and (c) the absence of a basic immunity to the antigens present in most older individuals as a result of previous contacts with influenzal viruses. Although it is impossible to decide among these factors, the booster effect of restimulation with small doses of antigen is a well known phenomenon in protective measures against other infectious agents. It is felt that such a mechanism may well be the explanation for the discrepancies between young children and older individuals in their response to vaccination against influenza.

Sign in / Sign up

Export Citation Format

Share Document